Summit Trail Advisors LLC Has $315,000 Stock Holdings in 10x Genomics (NASDAQ:TXG)

Summit Trail Advisors LLC increased its position in shares of 10x Genomics (NASDAQ:TXG - Free Report) by 251.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,039 shares of the company's stock after purchasing an additional 25,775 shares during the period. Summit Trail Advisors LLC's holdings in 10x Genomics were worth $315,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. FMR LLC increased its holdings in shares of 10x Genomics by 0.6% during the fourth quarter. FMR LLC now owns 13,454,434 shares of the company's stock worth $193,206,000 after buying an additional 86,455 shares in the last quarter. RA Capital Management L.P. bought a new position in shares of 10x Genomics in the fourth quarter valued at about $47,092,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of 10x Genomics by 10.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,116,573 shares of the company's stock valued at $30,394,000 after buying an additional 193,588 shares during the last quarter. Voloridge Investment Management LLC lifted its position in 10x Genomics by 12.1% during the 4th quarter. Voloridge Investment Management LLC now owns 1,585,965 shares of the company's stock worth $22,774,000 after buying an additional 171,161 shares in the last quarter. Finally, Two Sigma Investments LP grew its holdings in 10x Genomics by 291.2% during the 4th quarter. Two Sigma Investments LP now owns 1,319,487 shares of the company's stock worth $18,948,000 after acquiring an additional 982,203 shares during the last quarter. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

TXG has been the subject of a number of research analyst reports. Stephens reaffirmed an "overweight" rating and issued a $14.00 target price on shares of 10x Genomics in a research note on Thursday, May 15th. Morgan Stanley decreased their price objective on 10x Genomics from $26.00 to $18.00 and set an "overweight" rating on the stock in a research report on Monday, May 19th. Wall Street Zen downgraded 10x Genomics from a "buy" rating to a "hold" rating in a research report on Saturday, June 28th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 10x Genomics in a research note on Friday, June 27th. Finally, Canaccord Genuity Group cut their price target on 10x Genomics from $18.00 to $15.00 and set a "buy" rating on the stock in a research note on Monday, May 12th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $14.96.

Insider Activity at 10x Genomics

In other 10x Genomics news, CFO Adam Taich sold 4,044 shares of 10x Genomics stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $8.30, for a total value of $33,565.20. Following the sale, the chief financial officer directly owned 331,588 shares in the company, valued at approximately $2,752,180.40. The trade was a 1.20% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Serge Saxonov sold 9,343 shares of 10x Genomics stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $8.30, for a total transaction of $77,546.90. Following the completion of the sale, the chief executive officer owned 1,083,625 shares in the company, valued at $8,994,087.50. The trade was a 0.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 20,872 shares of company stock valued at $173,238. 10.03% of the stock is owned by corporate insiders.

10x Genomics Price Performance

Shares of NASDAQ TXG remained flat at $13.01 during midday trading on Friday. 2,002,826 shares of the stock were exchanged, compared to its average volume of 2,721,292. The business's 50 day moving average is $9.82 and its 200-day moving average is $11.13. 10x Genomics has a 52 week low of $6.78 and a 52 week high of $24.76.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.09. The company had revenue of $154.88 million for the quarter, compared to analysts' expectations of $131.91 million. 10x Genomics had a negative net margin of 25.14% and a negative return on equity of 23.22%. The business's quarterly revenue was down 2.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.50) earnings per share. On average, research analysts anticipate that 10x Genomics will post -1.43 EPS for the current fiscal year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.